. 2019 Nov 14;11:1758835919887044. doi: 10.1177/1758835919887044

Table 1.

Comparison of the five approved trastuzumab biosimilars.

Agent	Brand name	Approval	Indication	Trial population	Trial results
MYL-1401O	Ogivri	December 2017	Adjuvant early stage and metastatic breast cancer, metastatic gastric or GEJ adenocarcinoma	Metastatic breast cancer (n = 500)	MYL-1410 versus trastuzumab: Noninferior ORR: 69.6% versus 64% (HR 1.09; CI 95% 0.95–1.24)^12,13
CT-P6	Herzuma	December 2018	Adjuvant early stage and metastatic breast cancer	Early stage breast cancer (n = 549)	CT-P6 versus trastuzumab: noninferior pCR 46.8% versus 50.4% (risk ratio 0.92)^17,18
SB3	Ontruzant	January 2019	Adjuvant early stage and metastatic breast cancer, metastatic gastric or GEJ adenocarcinoma	Early stage breast cancer (n = 800)	SB3 versus trastuzumab: Equivalent in breast pCR 51.7% versus 42.0% (adjusted ratio 1.259)²⁰
PF-05280014	Trazimera	March 2019	Adjuvant early stage and metastatic breast cancer, metastatic gastric or GEJ adenocarcinoma	Metastatic breast cancer (n = 707)	PF-05280014 versus trastuzumab: Equivalent in breast ORR 62.5% versus 66.5% (RR for ORR 0.94)²⁴
ABP980	Kanjinti	June 2019	Adjuvant early stage and metastatic breast cancer, metastatic gastric or GEJ adenocarcinoma	Early stage breast cancer (n = 725)	ABP980 versus trastuzumab: pCR 48% versus 41% (risk ratio 1.188)²⁸

GEJ, gastroesophageal junction; HR, hazard ratio; ORR, Overall Response Rate; pCR, pathological complete response; RR, risk ratio.